Breaking News Bar

Business News and Information

Merck & Co (NY: MRK )

91.04 +0.45 (+0.50%)

Official Closing Price Updated: 7:00 PM EDT, Aug 17, 2022 Add to My Watchlist

Price and Volume

Volume	6,486,029
Open	90.34
Bid (Size)	90.81 (5)
Ask (Size)	92.17 (2)
Prev. Close	90.59
Today's Range	90.30 - 91.89
52wk Range	70.89 - 95.72
Shares Outstanding	2,531,374,696
Dividend Yield	2.86%

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Could This Company's HyBryte™ Provide A Safer, More Convenient Alternative To Cutaneous T-Cell Lymphoma Treatment?

Today 14:37 EDT

Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being cured.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

August 16, 2022

Via Benzinga

Performance

YTD	+18.43%	+18.43%
1 Month	-1.41%	-1.41%
3 Month	-1.15%	-1.15%
6 Month	+17.90%	+17.90%
1 Year	+15.49%	+15.49%

More News

3 Top Stocks to Invest In Right Now

August 16, 2022

Via InvestorPlace

Merck Bets $250M On Next-Gen Approach To mRNA For Infectious Diseases, Cancer

August 16, 2022

Via Benzinga

Seagen For Sale? This Acquisition Target Is 'Too Intriguing To Ignore,' RBC Says

August 16, 2022

Via Benzinga

Merck Re-enters Alzheimer's R&D With Research Pact With Cerevance

August 09, 2022

Via Benzinga

FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

August 16, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology

August 16, 2022

From Merck & Co., Inc.

Via Business Wire

AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use

August 16, 2022

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session

August 15, 2022

Via Benzinga

Seagen Suffers Loss In Arbitration Dispute Over ADC Technology

August 15, 2022

Via Benzinga

Does Merck Finally Have The Fodder It Needs To Buy Seagen?

August 12, 2022

Via Investor's Business Daily

Senate Finance Committee Expands Amgen's Tax Probe: Report

August 12, 2022

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session

August 12, 2022

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

August 11, 2022

Via Benzinga

Merck & Co Whale Trades For August 11

August 11, 2022

Via Benzinga

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments

August 11, 2022

Via Investor Brand Network

ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off

August 11, 2022

Via Benzinga

Stocks Log Solid Wins As Inflation Concerns Ease

August 10, 2022

Via Talk Markets

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

August 10, 2022

Via Benzinga

Benzinga Before The Bell: Elon Musk Sells $6.8B Tesla Shares, Nio Begins ES7 Test Drives, Coinbase Accused Of Misleading Investors And Other Top Financial Stories Wednesday, August 10

August 10, 2022

Via Benzinga

To Avoid Supply Crunch, FDA Temporarily Allows Higher Impurity Levels In Merck's Diabetes Drug: Report

August 10, 2022

Via Benzinga

The 3 Best Vanguard Funds to Buy in August

August 08, 2022

Via InvestorPlace

Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern

August 08, 2022

Via Benzinga

The Power of Science to Stop a Killer

August 08, 2022

Via Investor Brand Network

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

bottom clear

About Us